Clinical impact of lamivudine resistance in chronic hepatitis B [1]

Journal of Hepatology

Volumn 29, Issue 3, 1998, Pages 510-511

  Honkoop, P ^a   De Man, R A ^a   Niesters, H G M ^a   Schalm, S W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFECT; HEPATITIS B; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 0031831091     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80075-5     Document Type: Letter

References (5)

1. MM Bartholomew RW Jansen LJ Jeffers KR Reddy LC Johnson H Bunzendahl Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation Lancet 349 1997 20 22
2. P Honkoop HGM Niesters RA de Man ADME Osterhaus SW Schalm Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns J Hepatol 26 1997 1393 1395
3. HGM Niesters P Honkoop EB Haagsma RA de Man SW Schalm ADME Osterhaus Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine therapy J Infect Dis 177 1998 1382 1385
4. de Man RA A Bartholomeusz HGM Niesters P Zondervan SA Locarnini The sequential occurrence of viral mutations in a liver transplant recipient reinfected with hepatitis B: hepatitis B immune globulin escape famciclovir non-response, followed by lamivudine resistance in graft loss J Hepatol 1998 In press.
5. NWY Leung CL Lai YF Liaw TT Chang R Guan DI Tai Lamivudine (100 mg od) for 1 year significantly improves necro-inflammatory activity and reduces progression in fibrosis stage: results of a placebo-controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection [abstract] Hepatology 26 1997 357 (Suppl)